The Janus kinase 1/2 inhibitor baricitinib reduces biomarkers of joint destruction in moderate to severe rheumatoid arthritis

被引：0
|
作者：
Christian S. Thudium
Anne C. Bay-Jensen
Suntara Cahya
Ernst R. Dow
Morten A. Karsdal
Alisa E. Koch
Wenling Zhang
Robert J. Benschop
机构：
[1] Nordic Bioscience,
[2] Biomarkers and Research,undefined
[3] Eli Lilly and Company,undefined
来源：
Arthritis Research & Therapy | / 22卷
关键词：
Biomarkers; Baricitinib; Rheumatoid arthritis;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [41] Combination treatment with Janus kinase inhibitor and nintedanib for rheumatoid arthritis with progressive interstitial lung disease: A case report
    Mochizuki, Takeshi
    Yano, Koichiro
    Ikari, Katsunori
    Okazaki, Ken
    MODERN RHEUMATOLOGY CASE REPORTS, 2023, 7 (02) : 350 - 353
  • [42] The effectiveness of tofacitinib, a novel Janus kinase inhibitor, in the treatment of rheumatoid arthritis: a systematic review and meta-analysis
    Kawalec, Pawel
    Mikrut, Alicja
    Wisniewska, Natalia
    Pilc, Andrzej
    CLINICAL RHEUMATOLOGY, 2013, 32 (10) : 1415 - 1424
  • [43] The effectiveness of tofacitinib, a novel Janus kinase inhibitor, in the treatment of rheumatoid arthritis: a systematic review and meta-analysis
    Paweł Kawalec
    Alicja Mikrut
    Natalia Wiśniewska
    Andrzej Pilc
    Clinical Rheumatology, 2013, 32 : 1415 - 1424
  • [44] Involvement of fibroblast growth factor-2 in joint destruction of rheumatoid arthritis patients
    Manabe, N
    Oda, H
    Nakamura, K
    Kuga, Y
    Uchida, S
    Kawaguchi, H
    RHEUMATOLOGY, 1999, 38 (08) : 714 - 720
  • [45] TGF-β-activated kinase-1 inhibitor LL-Z1640-2 reduces joint inflammation and bone destruction in mouse models of rheumatoid arthritis by inhibiting NLRP3 inflammasome, TACE, TNF-α and RANKL expression
    Tenshin, Hirofumi
    Teramachi, Jumpei
    Ashtar, Mohannad
    Hiasa, Masahiro
    Inoue, Yusuke
    Oda, Asuka
    Tanimoto, Kotaro
    Shimizu, So
    Higa, Yoshiki
    Harada, Takeshi
    Oura, Masahiro
    Sogabe, Kimiko
    Hara, Tomoyo
    Sumitani, Ryohei
    Maruhashi, Tomoko
    Sebe, Mayu
    Tsutsumi, Rie
    Sakaue, Hiroshi
    Endo, Itsuro
    Matsumoto, Toshio
    Tanaka, Eiji
    Abe, Masahiro
    CLINICAL & TRANSLATIONAL IMMUNOLOGY, 2022, 11 (01)
  • [46] Hypereosinophilic syndrome-a rare adverse event of anti-cytokine treatment in rheumatoid arthritis resolved after Janus kinase inhibitor therapy
    Stenova, Emake
    Tarabcakova, Lenka
    Babal, Pavel
    Kasperova, Stela
    CLINICAL RHEUMATOLOGY, 2020, 39 (11) : 3507 - 3510
  • [47] ]Effects of Janus kinase inhibitor tofacitinib on circulating serum amyloid A and interleukin-6 during treatment for rheumatoid arthritis
    Migita, K.
    Izumi, Y.
    Jiuchi, Y.
    Kozuru, H.
    Kawahara, C.
    Izumi, M.
    Sakai, T.
    Nakamura, M.
    Motokawa, S.
    Nakamura, T.
    Kawakami, A.
    CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 2014, 175 (02) : 208 - 214
  • [48] Switching between Janus kinase inhibitor upadacitinib and adalimumab following insufficient response: efficacy and safety in patients with rheumatoid arthritis
    Fleischmann, Roy M.
    Blanco, Ricardo
    Hall, Stephen
    Thomson, Glen T. D.
    Van den Bosch, Filip E.
    Zerbini, Cristiano
    Bessette, Louis
    Enejosa, Jeffrey
    Li, Yihan
    Song, Yanna
    DeMasi, Ryan
    Song, In-Ho
    ANNALS OF THE RHEUMATIC DISEASES, 2021, 80 (04) : 432 - 439
  • [49] A highly selective, orally active inhibitor of Janus kinase 2, CEP-33779, ablates disease in two mouse models of rheumatoid arthritis
    Kristine L Stump
    Lily D Lu
    Pawel Dobrzanski
    Cynthia Serdikoff
    Diane E Gingrich
    Ben J Dugan
    Thelma S Angeles
    Mark S Albom
    Mark A Ator
    Bruce D Dorsey
    Bruce A Ruggeri
    Matthew M Seavey
    Arthritis Research & Therapy, 13
  • [50] Sarilumab reduces disease activity in rheumatoid arthritis patients with inadequate response to janus kinase inhibitors or tocilizumab in regular care in Germany
    Tony, Hans-Peter
    Feist, Eugen
    Aries, Peer Malte
    Zinke, Silke
    Krueger, Klaus
    Ahlers, Jonas
    Albrecht, Inka
    Barrionuevo, Christian
    Kalus, Stefanie
    Burkhardt, Harald
    RHEUMATOLOGY ADVANCES IN PRACTICE, 2022, 6 (01)
12345